Abstract
CHIP refers to the finding of one or more mutations affecting genes involved in hematological malignancies in patients (pts) without hematological disease per se. The main risk factor for developing CHIP is aging. An increased risk of developing CHIP has been recently identified in pts with solid tumors. Comprehensive data integrating the molecular and clinical characteristics of pts with solid tumors and CHIP remain limited.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
